HOVON
The Dutch-Belgian adult haematology trials group, one of Europe's largest engines of leukaemia, myeloma and lymphoma phase 3 trials.
Founded in 1985 and coordinated from Rotterdam, HOVON runs trials across the Netherlands, Belgium and partner countries, often jointly with the Swiss SAKK and the German and Nordic groups. Its AML trials defined intensive induction, consolidation and transplant strategies in adults and the elderly, HOVON-65/GMMG-HD4 established bortezomib in myeloma induction and maintenance, and HOVON lymphoma and CLL studies contribute to European standards. HOVON participates in the European Myeloma Network trials and runs a national data centre and biobank. Most Dutch adults with acute leukaemia are treated within or according to a HOVON protocol.
- AML trials (with SAKK)
- Myeloma (HOVON-65/GMMG-HD4, EMN trials)
- Lymphoma and CLL
- National haematology data centre
Pages like this
not linked directly; found by shared links- InstitutionAmerican Society of Hematology
Shares European Hematology Association, Hodgkin lymphoma, Minimal / molecular residual disease (MRD), Chronic lymphocytic leukaemia.
- CollectionLeukemia & Lymphoma Society (LLS)
Shares Hodgkin lymphoma, Chronic lymphocytic leukaemia, Multiple myeloma, Acute lymphoblastic leukaemia.
- TermUndetectable MRD (uMRD / MRD-negative)
Shares Venetoclax, Minimal / molecular residual disease (MRD), Chronic lymphocytic leukaemia, MRD / molecular residual disease testing.
- TermLeukaemia (tissue type)
Shares Venetoclax, Minimal / molecular residual disease (MRD), Chronic lymphocytic leukaemia, Multiple myeloma.
- TechnologyMultiparameter flow cytometry MRD
Shares Minimal / molecular residual disease (MRD), Chronic lymphocytic leukaemia, MRD / molecular residual disease testing, Multiple myeloma.
- InstitutionLYSA – The Lymphoma Study Association
Shares German Lymphoma Alliance, International Extranodal Lymphoma Study Group, Hodgkin lymphoma, Diffuse large B-cell lymphoma.
- TermFlow cytometry (immunophenotyping)
Shares Minimal / molecular residual disease (MRD), Chronic lymphocytic leukaemia, Multiple myeloma, Acute lymphoblastic leukaemia.
- IdeaPlan the second CAR-T target before the first one is lost
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Multiple myeloma, Acute lymphoblastic leukaemia.